Abstract
The binding of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein, gp120, to its cell surface receptor, CD4, represents a molecular interaction involving distinct alterations in protein structure. Consequently, the pattern of epitopes presented on the gp120-CD4 complex should differ from those on free gp120. To investigate this concept, mice were immunized with covalently crosslinked complexes of viral HIV-1IIIBgp120 and soluble CD4. Two monoclonal antibodies (MoAbs) obtained from the immunized mice exhibited a novel epitope specificity. The MoAbs were marginally reactive with HIV-1IIIBgp120, highly reactive with gp120-CD4 complexes, and unreactive with soluble CD4. The same pattern of reactivity was seen in solid-phase assays using HIV-1(451)gp120. A similar specificity for complexes was evident in flow cytometry experiments, in which MoAb reactivity was dependent upon the attachment of gp120 to CD4-positive cells. In addition, MoAb reactivity was detected upon the interaction of CD4 receptors with purified HIV-1IIIB virions. Notably, seroantibodies from HIV-positive individuals competed for MoAb binding, indicating that the epitope is immunogenic in humans. The results demonstrated that crosslinked gp120-CD...Continue Reading
Citations
Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·A M ThorntonK Ozato
Feb 24, 1999·AIDS Research and Human Retroviruses·H GoldingC Lapham
Jul 28, 2010·Journal of Virology·Xavier DervillezUrsula Dietrich
Nov 23, 2000·Journal of Virology·T R FoutsA L DeVico
Oct 17, 2001·Journal of Virology·C M FinneganA L DeVico
Apr 29, 2004·Journal of Virology·Hua-Xin LiaoBarton F Haynes
Dec 7, 2013·Retrovirology·Anna Roitburd-BermanJonathan M Gershoni
Nov 24, 1999·Biochemical and Biophysical Research Communications·A Yachou, R P Sékaly
Dec 19, 2013·Antiviral Research·Luis Menéndez-Arias, Mar Alvarez
Oct 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Anthony DeVicoRanajit Pal
Aug 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Timothy FoutsRanajit Pal
May 5, 1998·Molecular Immunology·B B Jrad, E Bahraoui
Jan 24, 2007·Vaccine·Gerard DevittValerie Bosch
Oct 4, 2015·Vaccine·Mark A KillickMaria A Papathanasopoulos
May 17, 2006·Microbes and Infection·Donato ZipetoUmberto Bertazzoni
Aug 3, 2004·Expert Review of Vaccines·Indresh K SrivastavaSusan W Barnett
Jun 24, 2009·Retrovirology·Barbara FalkensammerHeribert Stoiber
Jul 2, 2003·FEMS Immunology and Medical Microbiology·T R FoutsD M Hone
May 14, 2014·PloS One·Anne-Sophie DugastGalit Alter
Sep 13, 2014·PloS One·Svetlana RabinovichChristopher L Parks
Jun 22, 2012·PloS One·Luzia M MayrPhillipe N Nyambi
Mar 26, 2015·PLoS Pathogens·Meron MengistuAnthony L DeVico
Mar 19, 2013·PLoS Computational Biology·David K Johnson, John Karanicolas
Apr 19, 2006·Gastroenterology·Penelope D OttewellD Mark Pritchard
Jun 26, 2007·Advances in Pharmacology·Ponraj PrabakaranDimiter S Dimitrov
Feb 19, 2016·Journal of Virology·Gilad KaplanJonathan M Gershoni
Mar 18, 2000·The Journal of Biological Chemistry·B L WagnerM Montminy
Nov 13, 1998·Journal of Virology·N M StamatosT C VanCott
Nov 13, 1999·Journal of Virology·B J DoranzR W Doms
May 2, 2002·Vaccine·Anthony L DevicoDavid M Hone
Aug 1, 1997·Journal of Virology·S LeeH Golding